Esperion Therapeutics Reports $87.3 Million Revenue in Q3 2025, Despite $31.3 Million Net Loss

Esperion Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $87.3 million, a significant increase from $51.6 million in the same period last year. This growth was driven by a 30% rise in product sales, which reached $40.7 million compared to $31.1 million in Q3 2024, and a substantial increase in collaboration revenue, which surged to $46.7 million from $20.5 million. The company attributed the rise in product sales primarily to increased prescription volumes of its lead products, NEXLETOL and NEXLIZET.

Despite the revenue growth, Esperion reported a net loss of $31.3 million for the quarter, slightly higher than the $29.5 million loss recorded in Q3 2024. The increase in losses was largely due to a rise in operating expenses, which totaled $97.3 million, up from $67.7 million in the prior year. The cost of goods sold also saw a significant increase, rising to $41.3 million from $17.3 million, reflecting higher product sales and costs associated with collaboration agreements. Research and development expenses increased to $14.1 million, while selling, general, and administrative expenses rose to $41.8 million, reflecting ongoing commercialization efforts and legal costs related to patent litigation.

In terms of operational metrics, the company reported a total cash and cash equivalents balance of $92.4 million as of September 30, 2025, down from $144.8 million at the end of 2024. This decrease was primarily due to cash used in operating activities, which amounted to $58.3 million for the nine months ended September 30, 2025, compared to a net cash provided by operating activities of $11.3 million in the same period last year. The company’s total liabilities increased to $815.4 million, up from $732.5 million at the end of 2024, largely due to increased debt obligations and accrued liabilities.

Strategically, Esperion has been active in expanding its market presence and product offerings. The company received expanded indications for its products from the FDA in March 2024, which are expected to enhance their marketability. Additionally, Esperion has entered into various collaboration agreements, including a recent partnership with Otsuka Pharmaceutical for the commercialization of its products in Japan, which is anticipated to contribute to future revenue streams. The company is also preparing for potential approvals in Canada, Israel, and Australia, with expected timelines in late 2025 and 2026.

Looking ahead, Esperion anticipates continued operating losses as it invests in the commercialization of NEXLETOL and NEXLIZET and pursues additional research and development activities. The company has indicated that it may require additional financing to support its operations and product development, which could involve collaborations, strategic alliances, or public and private equity offerings. Management remains optimistic about the potential for future revenue growth driven by its product sales and collaboration agreements, although it acknowledges the inherent risks and uncertainties in the biopharmaceutical industry.